Medivation Inc. (MDVN)
  • Россия
  • Украина

Medivation Inc. (MDVN)

Contact Details

525 Market St Fl 36, San Francisco, California, USA 94105-2747
(415) 543-3470
525 Market St Fl 36, San Francisco, California, USA 94105-2747

General Information

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation`s current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer`s disease, Huntington`s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices

Contact Information

Phone(415) 543-3470
Customer Service Phone(800) 947-5227
Website 1
Thomson Reuters PermID4295902657


NamePositionTotal Annual CompensationYearPercent Change in Compensation
President and CEO$10,570,9462014359.5%
Former CFO, Former Other Executive Officer and Director$581,0902014-46.3%
General Counsel and Secretary$2,334,099201447.6%
Chief Medical Officer$3,501,4622014223.3%
Former Other Executive Officer$4,555,4722014359.1%
Other Executive Officer$2,666,0292014

Corporate Data


  • Pharmaceutical Preparation Manufacturing
  • Research and Development in Biotechnology

SIC Industries

  • Pharmaceutical Preparations
  • Biotechnical Research, Commercial

Company Size

Sales Volume$943 million


Ticker SymbolMDVN
ExchangeNASDAQ Global Market
Year Founded2004


Previous Close46.45
Bid45.24 x 500
Ask45.27 x 20,500
Day`s Range45.03 - 46.58
52-Week Range27.32 - 66.46
Average Volume (1M)3,980,976
Forward P/E42.1x
Trailing P/E62.35x
Market Cap.$7,628.67 Million
Last Dividend Amount0
1y Target Price Est.68


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue377,748260,665175,657129,188
Cost of Revenue----
Gross Profit377,748260,665175,657129,188
Research Development94,25945,87147,29444,676
Selling General and Administrative62,08975,80974,70883,939
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses156,348121,680122,002128,615
Other Income/Expenses Net----
Earnings Before Interest and Taxes221,400138,98553,655573
Interest Expense4881,0785,3095,608
Income Before Tax220,940124,85040,426(4,898)
Income Tax Expense78,43345,34014,600(1,780)
Minority Interest----
Net Income from Continuing Ops142,50779,51025,826(3,118)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income142,50779,51025,826(3,118)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares142,50779,51025,826(3,118)